How Envoy Medical, Inc.’s FDA pathway could influence the future of implantable hearing systems
Could fully implanted cochlear implants transform hearing restoration? Explore the regulatory, clinical, and market implications now.
Cryo-Cell avoided a delisting scare for now, but investors still face a 2027 countdown
Cryo-Cell avoided immediate delisting pressure. The harder test is whether its cord blood banking model can repair the balance sheet by 2027.
Why Kelun-Biotech’s sac-TMT review could reshape China’s lung cancer ADC market
ADC ambition meets Keytruda dominance. Kelun-Biotech’s sac-TMT filing could test how far TROP2 combinations can move in lung cancer.
Curaleaf adds Jacksonville Beach and Fernandina Beach dispensaries to deepen Florida reach
Curaleaf is adding Florida stores as cannabis investors demand proof of profitable scale. The next test is store productivity, not footprint.
Artivion just bought a bigger aortic future, but investors may not love the waiting game
Artivion’s aortic portfolio is getting stronger, but its 2026 outlook is getting weaker. Can Endospan turn strategy into growth?
Can Artiva Biotherapeutics, Inc. turn deep B-cell depletion into a scalable autoimmune treatment model?
Can AlloNK make autoimmune cell therapy scalable? Explore why Artiva Biotherapeutics, Inc.’s rheumatoid arthritis strategy matters.
Merck may have solved the hidden problem behind the oral PCSK9 race
Oral PCSK9 drugs need more than strong LDL data. Merck’s enlicitide paper tests whether peptide manufacturing can scale.
Why Oragenics, Inc. is betting on CardioDialysis technology to expand its TBI platform
Why is Oragenics, Inc. expanding into CardioDialysis for TBI treatment? Explore the strategy, risks, and future implications today.
Is Zentalis Pharmaceuticals, Inc. on track for accelerated approval in ovarian cancer
Can azenosertib secure accelerated approval? Explore how Zentalis Pharmaceuticals, Inc.’s trials could reshape ovarian cancer treatment.
What Madrigal Pharmaceuticals, Inc.’s siRNA deal signals for the future of MASH treatment
Can Madrigal Pharmaceuticals, Inc. reshape MASH treatment with ARO-PNPLA3? Discover what this precision strategy means for the future.